000272148 001__ 272148
000272148 005__ 20240929004931.0
000272148 0247_ $$2doi$$a10.1212/WNL.0000000000209766
000272148 0247_ $$2pmid$$apmid:39270149
000272148 0247_ $$2pmc$$apmc:PMC11399067
000272148 0247_ $$2ISSN$$a0028-3878
000272148 0247_ $$2ISSN$$a1526-632X
000272148 0247_ $$2altmetric$$aaltmetric:167307697
000272148 037__ $$aDZNE-2024-01139
000272148 041__ $$aEnglish
000272148 082__ $$a610
000272148 1001_ $$00000-0003-1290-0949$$aSon, Hye Joo$$b0
000272148 245__ $$aAssociation of Resilience-Related Life Experiences on Variability on Age of Onset in Dominantly Inherited Alzheimer Disease.
000272148 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2024
000272148 3367_ $$2DRIVER$$aarticle
000272148 3367_ $$2DataCite$$aOutput Types/Journal article
000272148 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1727091287_16291
000272148 3367_ $$2BibTeX$$aARTICLE
000272148 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272148 3367_ $$00$$2EndNote$$aJournal Article
000272148 520__ $$aIt remains unknown whether the associations between protective lifestyles and sporadic dementia risk reported in observational studies also affect age at symptom onset (AAO) in autosomal dominant Alzheimer disease (ADAD) with predominant genetic influences. We investigated the associations between resilience-related life experiences and interindividual AAO variability in ADAD.We performed a longitudinal and confirmatory analysis of the Dominantly Inherited Alzheimer Network prospective observational cohort (January 2009-June 2018, follow-up duration 2.13 ± 2.22 years), involving clinical, CSF, and lifestyle/behavioral assessments. We performed a 2-pronged comprehensive resilience assessment in each cohort. Cohort 1, incorporating the general resilience definition (cognitive maintenance [Clinical Dementia Rating = 0] despite high pathology), included carriers during the periods of significant CSFp-tau181 variability and grouped into resilience/resistance outcome bins according to the dichotomous pathologic and cognitive statuses, subcategorized by the estimated years from expected symptom onset (EYO). Cohort 2, focused on ADAD-specific genetically determined time frame characterizing the onset predictability, included asymptomatic participants with available preclinical lifestyle data and AAO outcomes and grouped into delayed or earlier AAO relative to the parental AAO. Associations of cognitive, CSFp-tau181, and lifestyle/behavioral predictors with binary outcomes were investigated using logistic regression.Of 320 carriers (age 38.19 ± 10.94 years, female 56.25%), cohort 1 included 218 participants (39.00 ± 9.37 years, 57.34%) and cohort 2 included 28 participants (43.34 ± 7.40 years, 71.43%). In cohort 1, 218 carriers after -20 EYO, when the interindividual variability (SD) of CSFp-tau181 first became more than twice greater in carriers than in noncarriers, were grouped into low-risk control (asymptomatic, low pathology, n = 103), high-resilience (asymptomatic despite high pathology, n = 60), low-resilience (symptomatic despite low pathology, n = 15), and susceptible control (symptomatic, high pathology, n = 40) groups. Multivariable predictors of high resilience, controlling for age and depression, included higher conscientiousness (odds ratio 1.051 [95% CI 1.016-1.086], p = 0.004), openness to experience (1.068 [1.005-1.135], p = 0.03) (vs. susceptible controls), and agreeableness (1.082 [1.015-1.153], p = 0.02) (vs. low resilience). From 1 to 3 years before parental AAO (cohort 2), the multivariable predictor of delayed AAO, controlling for CSFp-tau181, was higher conscientiousness (0.916 [0.845-0.994], p = 0.036).Among the cognitively and socially integrated life experiences associated with resilience, measures of conscientiousness were useful indicators for evaluating resilience and predicting future dementia onset in late preclinical ADAD.
000272148 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000272148 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000272148 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272148 650_7 $$2NLM Chemicals$$atau Proteins
000272148 650_2 $$2MeSH$$aHumans
000272148 650_2 $$2MeSH$$aFemale
000272148 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000272148 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000272148 650_2 $$2MeSH$$aAlzheimer Disease: epidemiology
000272148 650_2 $$2MeSH$$aMale
000272148 650_2 $$2MeSH$$aMiddle Aged
000272148 650_2 $$2MeSH$$aResilience, Psychological
000272148 650_2 $$2MeSH$$aAge of Onset
000272148 650_2 $$2MeSH$$aAdult
000272148 650_2 $$2MeSH$$aLongitudinal Studies
000272148 650_2 $$2MeSH$$aCohort Studies
000272148 650_2 $$2MeSH$$aProspective Studies
000272148 650_2 $$2MeSH$$atau Proteins: genetics
000272148 650_2 $$2MeSH$$aLife Style
000272148 650_2 $$2MeSH$$aLife Change Events
000272148 650_2 $$2MeSH$$aAged
000272148 693__ $$0EXP:(DE-2719)DIAN-20090101$$5EXP:(DE-2719)DIAN-20090101$$eLongitudinal Study on Dominantly Inherited Alzheimer's Disease$$x0
000272148 7001_ $$aKim, Jae Seung$$b1
000272148 7001_ $$00000-0002-7729-1702$$aBateman, Randall J$$b2
000272148 7001_ $$aKim, Seonok$$b3
000272148 7001_ $$00000-0002-2137-7750$$aLlibre-Guerra, Jorge J$$b4
000272148 7001_ $$00000-0001-5133-5538$$aDay, Gregory S$$b5
000272148 7001_ $$00000-0002-7792-1698$$aChhatwal, Jasmeer P$$b6
000272148 7001_ $$00000-0002-5096-4962$$aBerman, Sarah B$$b7
000272148 7001_ $$00000-0003-2967-9662$$aSchofield, Peter R$$b8
000272148 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b9
000272148 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b10
000272148 7001_ $$0P:(DE-HGF)0$$aLee, Jae-Hong$$b11
000272148 7001_ $$00000-0002-3443-7716$$aPerrin, Richard J$$b12
000272148 7001_ $$00000-0001-9820-5618$$aMorris, John C$$b13
000272148 7001_ $$00000-0002-0276-2899$$aCruchaga, Carlos$$b14
000272148 7001_ $$00000-0002-7802-3371$$aHassenstab, Jason$$b15
000272148 7001_ $$00000-0002-2631-0942$$aSalloway, Stephen P$$b16
000272148 7001_ $$aLee, Jai-Hyuen$$b17
000272148 7001_ $$aDaniels, Alisha$$b18
000272148 7001_ $$aNetwork, Dominantly Inherited Alzheimer$$b19$$eCollaboration Author
000272148 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000209766$$gVol. 103, no. 7, p. e209766$$n7$$pe209766$$tNeurology$$v103$$x0028-3878$$y2024
000272148 8564_ $$uhttps://pub.dzne.de/record/272148/files/DZNE-2024-01139.pdf$$yOpenAccess
000272148 8564_ $$uhttps://pub.dzne.de/record/272148/files/DZNE-2024-01139.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272148 909CO $$ooai:pub.dzne.de:272148$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000272148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000272148 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000272148 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000272148 9141_ $$y2024
000272148 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000272148 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000272148 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2022$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2022$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272148 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-21$$wger
000272148 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000272148 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000272148 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x0
000272148 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000272148 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000272148 980__ $$ajournal
000272148 980__ $$aVDB
000272148 980__ $$aUNRESTRICTED
000272148 980__ $$aI:(DE-2719)1210001
000272148 980__ $$aI:(DE-2719)1111015
000272148 980__ $$aI:(DE-2719)1111016
000272148 9801_ $$aFullTexts